Literature DB >> 17114012

Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Siong-Seng Liau1, Stanley W Ashley, Edward E Whang.   

Abstract

The high mobility group A1 (HMGA1) proteins are overexpressed in pancreatic cancers. They are architectural nuclear proteins, which regulate expression of multiple genes implicated in the malignant phenotype. In this study, we hypothesized that HMG A1 silencing will promote chemosensitivity in pancreatic adenocarcinoma. We studied highly malignant pancreatic adenocarcinoma cell lines (MiaPaCa2 and PANC1). Lentiviral short-hairpin RNA (shHMGA1) expression vectors targeting HMGA1 were used for generation of lentiviral particles. Stable transfectants were developed after lentiviral transduction. Nuclear expression of HMGA1 was assayed using Western blot analysis. Chemosensitivity to gemcitabine was determined by IC50 analysis. Caspase activity was quantitated using fluorometric caspase profiling. Apoptosis was assessed by flow cytometric analysis. Lentivirus-mediated RNA interference resulted in 90% silencing of HMGA1 expression in each of MiaPaCa2 and PANC1 cell lines. HMGA1 silencing enhanced chemosensitivity to gemcitabine with an approximately 50% reduction in IC50 in each cell line. Lentivirus-mediated HMGA1 silencing promoted the activation of caspases 3, 2, 9, and 8, on exposure to gemcitabine. HMGA1 silencing resulted in reduction in Akt kinase activity. Lentivirus-mediated RNA interference of HMGA1 promoted chemosensitivity to gemcitabine in pancreatic adenocarcinoma. HMGA1 may represent a novel therapeutic target in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114012     DOI: 10.1016/j.gassur.2006.06.011

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  41 in total

1.  Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  S S Ng; M S Tsao; T Nicklee; D W Hedley
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 2.  Surgery for pancreatic cancer: recent controversies and current practice.

Authors:  Curtis J Wray; Syed A Ahmad; Jeffrey B Matthews; Andrew M Lowy
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

Review 3.  Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.

Authors:  Peter Manilla; Tessio Rebello; Cathleen Afable; Xiaobin Lu; Vladimir Slepushkin; Laurent M Humeau; Kathy Schonely; Yajin Ni; Gwendolyn K Binder; Bruce L Levine; Rob-Roy MacGregor; Carl H June; Boro Dropulic
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

4.  Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.

Authors:  M S Tsao; S Chow; D W Hedley
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

5.  HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma.

Authors:  W Czyz; E Balcerczak; M Jakubiak; Z Pasieka; K Kuzdak; M Mirowski
Journal:  Langenbecks Arch Surg       Date:  2004-04-24       Impact factor: 3.445

6.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells.

Authors:  Nathan R Treff; Derek Pouchnik; Gregory A Dement; Rachel L Britt; Raymond Reeves
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

8.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.

Authors:  Bridget N Fahy; Michael G Schlieman; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Am Coll Surg       Date:  2004-04       Impact factor: 6.113

9.  HMGA1 inhibits the function of p53 family members in thyroid cancer cells.

Authors:  Francesco Frasca; Alessandra Rustighi; Roberta Malaguarnera; Sandro Altamura; Paolo Vigneri; Giannino Del Sal; Vincenzo Giancotti; Vincenzo Pezzino; Riccardo Vigneri; Guidalberto Manfioletti
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

10.  Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome.

Authors:  D Thanos; T Maniatis
Journal:  Cell       Date:  1995-12-29       Impact factor: 41.582

View more
  22 in total

1.  Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.

Authors:  Chun Jiang; Xiao-Ping Yi; Hong Shen; Yi-Xiong Li
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

Review 3.  Pancreatic cancer: molecular pathogenesis and new therapeutic targets.

Authors:  Han H Wong; Nicholas R Lemoine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-09       Impact factor: 46.802

Review 4.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

5.  Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.

Authors:  Nunzio Antonio Cacciola; Romina Sepe; Floriana Forzati; Antonella Federico; Simona Pellecchia; Umberto Malapelle; Alfonso De Stefano; Danilo Rocco; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-28       Impact factor: 3.000

6.  High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Flavio Rocha; Evan Matros; Mark Redston; Edward Whang
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

7.  CXCR7 expression in nasopharyngeal carcinoma tissues correlates with disease severity.

Authors:  Li Zhu; Ke Luo; Xiu-Hui Gu; Nan Hou; Chao-Pin Huang; Qing Lou; Xiao-Zheng Dai; Kun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Edward Whang
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 9.  Nuclear functions of the HMG proteins.

Authors:  Raymond Reeves
Journal:  Biochim Biophys Acta       Date:  2009-09-11

10.  HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma.

Authors:  Alexandra C Hristov; Leslie Cope; Francescopaolo Di Cello; Marcelo Delos Reyes; Mansher Singh; Joelle A Hillion; Amy Belton; Biju Joseph; Andrew Schuldenfrei; Christine A Iacobuzio-Donahue; Anirban Maitra; Linda M S Resar
Journal:  Mod Pathol       Date:  2009-10-09       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.